Cargando…

Hepatocyte growth factor predicts failure of Fontan circulation

AIMS: This study aimed to assess the value of the hepatocyte growth factor (HGF) as an independent predictor of a Fontan circulation failure. METHODS AND RESULTS: This retrospective case–control study included 34 consecutive patients (19 men and 15 women) who underwent a post‐operative cardiac cathe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kojima, Takuro, Taki, Moe, Toda, Koichi, Muraji, Shota, Yoshiba, Shigeki, Kobayshi, Toshiki, Sumitomo, Naokata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754719/
https://www.ncbi.nlm.nih.gov/pubmed/32914543
http://dx.doi.org/10.1002/ehf2.12943
_version_ 1783626248104181760
author Kojima, Takuro
Taki, Moe
Toda, Koichi
Muraji, Shota
Yoshiba, Shigeki
Kobayshi, Toshiki
Sumitomo, Naokata
author_facet Kojima, Takuro
Taki, Moe
Toda, Koichi
Muraji, Shota
Yoshiba, Shigeki
Kobayshi, Toshiki
Sumitomo, Naokata
author_sort Kojima, Takuro
collection PubMed
description AIMS: This study aimed to assess the value of the hepatocyte growth factor (HGF) as an independent predictor of a Fontan circulation failure. METHODS AND RESULTS: This retrospective case–control study included 34 consecutive patients (19 men and 15 women) who underwent a post‐operative cardiac catheterization after a Fontan operation at the Saitama Medical University International Medical Center between April 2017 and December 2019. We divided the patients into two groups according to the HGF level: HGF < 0.4 ng/mL (n = 20, normal HGF group) and HGF ≥ 0.4 ng/mL (n = 14, elevated HGF group). The age at the time of the cardiac catheterization was 59.3 ± 7.9 months. The range of the duration between the Fontan operation and the cardiac catheterization was 37.5 ± 7.9 months. The age (P = 0.417), gender (P = 0.08), morphology of the functional ventricle (P = 0.99), presence or closure of the Fontan fenestration (P = 0.704), and rate of medication use (angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers) (P = 0.99) were equivalent between the two groups. Laboratory parameters including the brain natriuretic peptide level (P = 0.085), serum creatinine level (P = 0.27), and aspartate aminotransferase level (P = 0.235) were similar between the two groups. The elevated HGF group had a higher C‐reactive protein level than the normal HGF group (0.42 ± 0.14 and 0.05 ± 0.01 mg/dL, P = 0.005). The elevated HGF group had a higher central venous pressure (CVP) level than the normal HGF group (13.4 ± 0.7 and 9.7 ± 0.4 mmHg, P < 0.0001), and the HGF was positively correlated with the CVP (P = 0.0004, r (2) = 0.33). The SvO(2) level was significantly lower in the elevated HGF group than in the normal HGF group (61.9 ± 2.3% and 75.0 ± 1.2%, P < 0.0001), and the HGF was negatively correlated with the SvO(2) (P < 0.0001, r (2) = 0.65). Of the 34 patients, six underwent catheter interventions. Patients who underwent catheter interventions had a higher HGF level than those who did not (0.44 ± 0.03 and 0.37 ± 0.01 ng/mL, P = 0.032). The receiver operating characteristic curve created for the discrimination of a catheter intervention revealed that an HGF value of >0.405 ng/mL could detect the need for a catheter intervention with 75.0% sensitivity and 83.3% specificity. A multivariable regression analysis showed that an elevated HGF was an independent predictor of an elevated CVP (β‐coefficient 21.2, SE 5.5, P = 0.0005) and decreased SvO(2) (β‐coefficient −92.9, SE 12.4, P < 0.0001). CONCLUSIONS: The HGF is an independent predictor of a failure of a Fontan circulation. The HGF is an indicator for an additional catheter intervention after a Fontan operation.
format Online
Article
Text
id pubmed-7754719
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77547192020-12-23 Hepatocyte growth factor predicts failure of Fontan circulation Kojima, Takuro Taki, Moe Toda, Koichi Muraji, Shota Yoshiba, Shigeki Kobayshi, Toshiki Sumitomo, Naokata ESC Heart Fail Original Research Articles AIMS: This study aimed to assess the value of the hepatocyte growth factor (HGF) as an independent predictor of a Fontan circulation failure. METHODS AND RESULTS: This retrospective case–control study included 34 consecutive patients (19 men and 15 women) who underwent a post‐operative cardiac catheterization after a Fontan operation at the Saitama Medical University International Medical Center between April 2017 and December 2019. We divided the patients into two groups according to the HGF level: HGF < 0.4 ng/mL (n = 20, normal HGF group) and HGF ≥ 0.4 ng/mL (n = 14, elevated HGF group). The age at the time of the cardiac catheterization was 59.3 ± 7.9 months. The range of the duration between the Fontan operation and the cardiac catheterization was 37.5 ± 7.9 months. The age (P = 0.417), gender (P = 0.08), morphology of the functional ventricle (P = 0.99), presence or closure of the Fontan fenestration (P = 0.704), and rate of medication use (angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers) (P = 0.99) were equivalent between the two groups. Laboratory parameters including the brain natriuretic peptide level (P = 0.085), serum creatinine level (P = 0.27), and aspartate aminotransferase level (P = 0.235) were similar between the two groups. The elevated HGF group had a higher C‐reactive protein level than the normal HGF group (0.42 ± 0.14 and 0.05 ± 0.01 mg/dL, P = 0.005). The elevated HGF group had a higher central venous pressure (CVP) level than the normal HGF group (13.4 ± 0.7 and 9.7 ± 0.4 mmHg, P < 0.0001), and the HGF was positively correlated with the CVP (P = 0.0004, r (2) = 0.33). The SvO(2) level was significantly lower in the elevated HGF group than in the normal HGF group (61.9 ± 2.3% and 75.0 ± 1.2%, P < 0.0001), and the HGF was negatively correlated with the SvO(2) (P < 0.0001, r (2) = 0.65). Of the 34 patients, six underwent catheter interventions. Patients who underwent catheter interventions had a higher HGF level than those who did not (0.44 ± 0.03 and 0.37 ± 0.01 ng/mL, P = 0.032). The receiver operating characteristic curve created for the discrimination of a catheter intervention revealed that an HGF value of >0.405 ng/mL could detect the need for a catheter intervention with 75.0% sensitivity and 83.3% specificity. A multivariable regression analysis showed that an elevated HGF was an independent predictor of an elevated CVP (β‐coefficient 21.2, SE 5.5, P = 0.0005) and decreased SvO(2) (β‐coefficient −92.9, SE 12.4, P < 0.0001). CONCLUSIONS: The HGF is an independent predictor of a failure of a Fontan circulation. The HGF is an indicator for an additional catheter intervention after a Fontan operation. John Wiley and Sons Inc. 2020-09-10 /pmc/articles/PMC7754719/ /pubmed/32914543 http://dx.doi.org/10.1002/ehf2.12943 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Kojima, Takuro
Taki, Moe
Toda, Koichi
Muraji, Shota
Yoshiba, Shigeki
Kobayshi, Toshiki
Sumitomo, Naokata
Hepatocyte growth factor predicts failure of Fontan circulation
title Hepatocyte growth factor predicts failure of Fontan circulation
title_full Hepatocyte growth factor predicts failure of Fontan circulation
title_fullStr Hepatocyte growth factor predicts failure of Fontan circulation
title_full_unstemmed Hepatocyte growth factor predicts failure of Fontan circulation
title_short Hepatocyte growth factor predicts failure of Fontan circulation
title_sort hepatocyte growth factor predicts failure of fontan circulation
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754719/
https://www.ncbi.nlm.nih.gov/pubmed/32914543
http://dx.doi.org/10.1002/ehf2.12943
work_keys_str_mv AT kojimatakuro hepatocytegrowthfactorpredictsfailureoffontancirculation
AT takimoe hepatocytegrowthfactorpredictsfailureoffontancirculation
AT todakoichi hepatocytegrowthfactorpredictsfailureoffontancirculation
AT murajishota hepatocytegrowthfactorpredictsfailureoffontancirculation
AT yoshibashigeki hepatocytegrowthfactorpredictsfailureoffontancirculation
AT kobayshitoshiki hepatocytegrowthfactorpredictsfailureoffontancirculation
AT sumitomonaokata hepatocytegrowthfactorpredictsfailureoffontancirculation